All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Olutasidenib in patients with AML following venetoclax exposure: Final 5-year results from a phase II trial
Bookmark this article
|
Final 5-year results from a phase II trial (NCT02719574) evaluating the efficacy and safety of olutasidenib in a subgroup of patients with IDH1mut AML following exposure to venetoclax were presented by Jorge Cortes at the SOHO 2024 Annual Meeting.1 A total of 18 adult patients, with median age of 74 years, were included. Patients received olutasidenib 150 mg alone (n = 16) or in combination with standard of care (n = 2). The median duration of prior venetoclax treatment was 5.4 months.1 |
| Key learnings |
| Olutasidenib resulted in ORR/CRc in 50% of all patients previously exposed to venetoclax, including CR/CRh in 39% and CRi in 11% of patients. |
| Of the 18 patients, 16 were R/R to venetoclax. Among these patients, treatment with olutasidenib resulted in ORR/CRc, CR/CRh, and CRi in 44%, 31%, and 13%, respectively. Median time to achieve CR/CRh was 2.1 months and the estimated duration of CR/CRh response was ≥18 months in 80% of patients. |
| In the pivotal cohort of 12 patients with R/R AML post venetoclax, olutasidenib was associated with an ORR/CRc of 50%, CR/CRh of 33%, and CRi of 17%. The median time to achieve CR/CRh was 2.4 months and the estimated duration of CR/CRh response was ≥18 months in 75% of patients. |
| Two patients with CRi with prior venetoclax received maintenance treatment with olutasidenib. Both patients showed improved CR, with a CR duration of 15.7 months and >31.3 months (ongoing), respectively. |
| All patients experienced ≥1 AE, with 89% reporting Grade 3−5 AEs. The most common Grade 3 and 4 AEs were anemia (33%) and neutropenia (22%), respectively. |
| The results suggested that olutasidenib led to deep and durable remissions in patients with IDH1mut AML who were R/R to a prior venetoclax regimen. In those achieving CRi with venetoclax, maintenance with olutasidenib resulted in improved CR. However, the study was limited by its small sample size. |
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; CR, complete remission; CRc, composite CR (CR+CRh+CRi); CRh, CR with partial hematologic recovery; CRi, CR with incomplete hematologic recovery; IDH1mut, IDH1 mutated; ORR, overall response rate; R/R, relapsed/refractory; SOHO, Society of Hematologic Oncology.
- Cortes J. Response to olutasidenib in patients with acute myeloid leukemia (AML) following venetoclax failure. Poster# AML-532. Presented at: Society of Hematologic Oncology 2024 Annual Meeting; Sep 4–7, 2024; Houston, US.
Your opinion matters
28 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox